Deal Ends Today·Save 35% annual plan
GIP/GLP-1 receptor agonistReviewed for 2026 plan year

Does EmblemHealth Cover Mounjaro?

The verdict

Conditional on most plans

EmblemHealth covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. Mounjaro is not covered for weight loss under any EmblemHealth line. The weight-loss tirzepatide product is Zepbound, with separate and often-excluded coverage. New York Medicaid covers diabetes GLP-1s but does not cover weight-loss GLP-1s — a sharp contrast to neighboring New Jersey. Verify tier and prior-auth criteria on the EmblemHealth formulary.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with EmblemHealth using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
EmblemHealth drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes only — not weight loss. The weight-loss tirzepatide product is Zepbound, a separate FDA approval.

    FDA drug labeling, Mounjaro (tirzepatide) prescribing information

  • New York Medicaid covers diabetes GLP-1s but does not cover weight-loss GLP-1s — in contrast to neighboring New Jersey, where NJ Medicaid covers some weight-loss GLP-1s with PA.

    New York State Department of Health, Medicaid Preferred Drug Program

  • The 2026 Medicare Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach the cap within 2–3 months and pay $0 for the rest of the year.

    CMS.gov, Medicare Part D Redesign 2025–2026

Plan types

Medicare vs. commercial coverage

Whether EmblemHealth covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Medicare Part D covers Mounjaro for type 2 diabetes only — not weight loss — at a specialty or non-preferred tier with prior authorization. The 2026 out-of-pocket cap is $2,100; most continuous users reach it within 2–3 months and pay $0 for the rest of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month, July 1, 2026 – Dec 31, 2027), which covers weight-loss-approved products only. Lilly savings card is not usable by Medicare beneficiaries. Verify your specific EmblemHealth Medicare plan formulary each year.

Commercial / Employer

Group & marketplace plans

Conditional

Commercial and employer-sponsored EmblemHealth plans cover Mounjaro for type 2 diabetes with prior authorization; off-label weight-loss use (diagnosis code E66.x) is denied. ACA/Individual plans cover Mounjaro for T2D with PA; weight-loss GLP-1s are commonly excluded. New York Medicaid covers diabetes GLP-1s (including Mounjaro) with PA at nominal cost-share, but does NOT cover weight-loss GLP-1s — EmblemHealth's large NYC Medicaid population faces this restriction. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card (excludes Medicare, Medicaid, and government programs; card expires 12/31/2026). Without coverage on a commercial plan, the card reduces cost to $499/month (max $647/month, up to 13 fills). Verify tier and cost-share on the EmblemHealth formulary.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills; expires 12/31/2026). Excludes all government programs.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Varies by plan tier — verify on EmblemHealth formulary or member services. Commercially insured patients with coverage may pay as little as $25/month via the Lilly savings card.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

Lilly Mounjaro Savings Card: commercially insured patients with coverage as little as $25/mo for 1–3 month supply; without coverage $499/mo (up to 13 fills, expires 12/31/2026). Not available to Medicare, Medicaid, Medicare Advantage, or government program beneficiaries.

Reduced copay through the assistance program, where eligible.

All figures are estimates; actual cost-share varies by plan tier, pharmacy, and deductible status. Confirm with EmblemHealth formulary or member services. Medicare Part D: 25% coinsurance after deductible until the $2,100 OOP cap; MFN $245/month mid-2026. NY Medicaid nominal cost-share.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Search the EmblemHealth formulary or drug list

    Visit the EmblemHealth member portal or formulary search and enter 'Mounjaro' or 'tirzepatide.' Confirm the tier, prior authorization requirement, and cost-share for your specific plan type (commercial, Medicare, or Medicaid/CHIP).

  2. 2

    Have your prescriber prepare the prior authorization

    Your prescriber will need to document your confirmed T2D diagnosis (ICD-10 E11.x), an A1c of 6.5% or higher within about 90 days, and a trial or failure of metformin. EmblemHealth is a major New York City-area insurer — your prescriber may be familiar with EmblemHealth's PA process, but confirming current criteria on the plan formulary is always recommended.

  3. 3

    Call EmblemHealth member services if coverage is unclear

    Call the number on the back of your EmblemHealth card and ask: Is Mounjaro covered for type 2 diabetes on my plan? What tier? Is prior authorization required? What is my estimated cost-share? If you are on NY Medicaid through EmblemHealth, note that weight-loss GLP-1s are not covered — but diabetes coverage for Mounjaro is unaffected.

If it's denied

Options if EmblemHealth won't cover Mounjaro

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Ozempic (semaglutide)

FDA-approved for type 2 diabetes. Covered with PA across EmblemHealth commercial and NY Medicaid plans; often placed ahead of Mounjaro in step-therapy sequences.

Trulicity (dulaglutide)

FDA-approved for T2D. GLP-1 alternative; often preferred tier with a lower list price than Mounjaro. Verify on EmblemHealth formulary.

Jardiance (empagliflozin) or Farxiga (dapagliflozin)

SGLT2 inhibitors approved for T2D with cardiovascular and renal benefits. May be part of step-therapy requirements before GLP-1 approval on EmblemHealth plans.

Zepbound (tirzepatide) — weight loss only

Same molecule as Mounjaro but FDA-approved for chronic weight management and obstructive sleep apnea — not diabetes. Has separate coverage from Mounjaro. New York Medicaid does not cover weight-loss GLP-1s, making Zepbound unavailable on EmblemHealth Medicaid for weight loss.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

No. EmblemHealth does not cover Mounjaro for weight loss under any line of business. Mounjaro is FDA-approved for type 2 diabetes only, and off-label weight-loss prescriptions coded with obesity diagnoses are denied. The weight-loss tirzepatide product is Zepbound, with separate coverage. New York Medicaid does not cover weight-loss GLP-1s at all — so Zepbound is also unavailable on the Medicaid line for weight loss. Verify on the EmblemHealth formulary.

No. New York Medicaid does not cover weight-loss GLP-1s, in contrast to neighboring New Jersey where NJ Medicaid covers some weight-loss GLP-1s with PA. EmblemHealth's large NYC Medicaid population is subject to NY's restriction. Mounjaro is covered for type 2 diabetes under NY Medicaid with PA — this restriction applies only to the weight-loss indication (Zepbound, Wegovy, Saxenda).

EmblemHealth's PA for Mounjaro typically requires a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within approximately 90 days, and a trial or documented failure of metformin (plus often one additional agent). Age 18 or older is required. Quantity limit is typically 4 pens per 28 days. Verify specific EmblemHealth criteria on the plan formulary or member services before submission.

Yes, if you have commercial EmblemHealth coverage and Mounjaro is on your plan, you may pay as little as $25/month via the Lilly savings card. Without commercial coverage, the card reduces cost to $499/month (max $647/month, up to 13 fills, expires 12/31/2026). The card is not available to Medicare Part D, Medicare Advantage, Medicaid, or any government program beneficiaries — including EmblemHealth Medicaid enrollees.

No. The 2026 Medicare GLP-1 Bridge ($50/month copay, July 1, 2026 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is a diabetes drug. Medicare covers Mounjaro for type 2 diabetes under standard Part D with prior authorization, specialty-tier cost-share, and the $2,100 annual OOP cap.

The Curex GLP-1 program

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

EmblemHealth covers Mounjaro for diabetes only, not weight loss — and NY Medicaid does not cover weight-loss GLP-1s. For patients who want tirzepatide access without insurance, compounded tirzepatide from $149/mo (and compounded semaglutide from $49/mo) is available at getcurex.com/cl/glp — no insurance required, no prior authorization. This is compounded tirzepatide and is not the same medication as Mounjaro or Zepbound. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with EmblemHealth before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Insurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.